Pomerantz LLP is investigating Sanara MedTech and its officers for potential securities fraud following the company's announcement to discontinue its Tissue Health Plus program. The shutdown led to a $31.2 million net loss and a $26.5 million asset impairment charge, causing Sanara's stock to drop nearly 25% on November 12, 2025. This investigation aims to determine if unlawful business practices occurred, impacting investors. Investors affected are encouraged to contact Pomerantz LLP for potential class action participation.
The US government, under the Trump administration, is negotiating to take equity stakes in domestic drone manufacturers to accelerate production, reduce costs, and lessen dependence on Chinese drone components. This move supports the 'Drone Dominance...
Bank of N.T. Butterfield announced it will acquire CIBC's 91.7% stake in CIBC Caribbean Bank Limited for approximately $1.8 billion, combining cash and shares. This acquisition aims to create a larger banking and wealth management platform in the Car...
Peec AI, an AI search analytics platform, surpassed $10 million in annual recurring revenue just 16 months after launch, doubling revenue in the last five months. The company is expanding rapidly, opening its first US office in New York to meet growi...
The National Crime Prevention Council (NCPC) has called on lawmakers to reject the House's Kids Internet and Digital Safety Act (H.R. 7757), criticizing it as insufficient for protecting children online. NCPC argues the bill weakens state powers and ...
Fannie Mae has started marketing a sale of approximately 2,333 reperforming loans with an unpaid principal balance of about $565 million. These loans were previously delinquent but have since become current. Buyers must offer loss mitigation options,...
